← Leaderboards
Sihem Boudina
University Of Utah
$6,642,517
Attributed
$8,665,301
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,665,301 · 5
By mechanism
R01$8,665,301 · 5
Top collaborators
- Patrice Mimche4 shared
- Kent Lai2 shared
- Eva Morava-Kozicz2 shared
Most similar at University Of Utah
Same institution · by research overlap
- John David Symons$3,553,170
- Patrice Mimche$4,267,251
- Christopher E Hopkins$1,657,693
- Julianne H. Grose$1,365,304
Others in their field
Top investigators on “Metabolic”
- David M Nathan · Massachusetts Institute Of Technology$157,845,616
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$141,260,706
- John M Lachin · George Washington University$139,991,329
- Randall J Bateman · Washington University$124,168,384
- Carol Nesel · Westat$116,355,411
Research focus
MetabolicMouse ModelAffectPathway InteractionsAdultIn VivoMitochondriaLiverPlayMediatingDietObesityInsightMetabolismExhibitsHomeostasisProteinsMetabolic SyndromeRegulationResponseCellsChildKnockout MiceCardiovascular Diseases
Grant awards (17)
Pathobiological mechanisms of cardiac disease in PGM1-CDG$651,868
R01 · FY2025 · HL
Pathobiological mechanisms of cardiac disease in PGM1-CDG$659,131
R01 · FY2024 · HL
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$538,034
R01 · FY2024 · DK
The Role of PRDM16 in Cardiac Development and Cardiomyopathy$686,398
R01 · FY2023 · HL · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$560,483
R01 · FY2023 · DK
The Role of PRDM16 in Cardiac Development and Cardiomyopathy$686,398
R01 · FY2022 · HL · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$599,169
R01 · FY2022 · DK
The Role of PRDM16 in Cardiac Development and Cardiomyopathy$681,823
R01 · FY2021 · HL · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$599,884
R01 · FY2021 · DK
The Role of PRDM16 in Cardiac Development and Cardiomyopathy$733,588
R01 · FY2020 · HL · contact PI
Novel pathways for fat burning that protects from high fat diet-induced metabolic$324,075
R01 · FY2017 · DK · contact PI
Post-Developmental Adipocyte Autophagy in Control of Insulin-Glucose Homeostasis$324,075
R01 · FY2017 · DK · contact PI
Post-Developmental Adipocyte Autophagy in Control of Insulin-Glucose Homeostasis$324,075
R01 · FY2016 · DK · contact PI
Novel pathways for fat burning that protects from high fat diet-induced metabolic$324,075
R01 · FY2016 · DK · contact PI
Novel pathways for fat burning that protects from high fat diet-induced metabolic$324,075
R01 · FY2015 · DK · contact PI
Novel pathways for fat burning that protects from high fat diet-induced metabolic$324,075
R01 · FY2014 · DK · contact PI
Novel pathways for fat burning that protects from high fat diet-induced metabolic$324,075
R01 · FY2013 · DK · contact PI